I am a
Home I AM A Search Login

Papers of the Week


Papers: 14 Jan 2023 - 20 Jan 2023


2023 Jan 16


J Headache Pain


24


1

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.

Authors

Troy E, Shrukalla AA, Buture A, Conaty K, Macken E, Lonergan R, Melling J, Long N, Shaikh E, Birrane K, Tomkins EM, Goadsby PJ, Ruttledge MH
J Headache Pain. 2023 Jan 16; 24(1):5.
PMID: 36647006.

Abstract

Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult to treat cases. Calcitonin gene-related peptide monoclonal antibodies are a relatively novel molecular treatment for episodic and chronic migraine that have been shown to be effective in short duration clinical trials in approximately 40-50% of all chronic migraine patients. Patient Related Outcome Measures (PROM) or Quality of Life (QoL) questionnaires are used to help measure response to treatment in migraine. Although some open label extension studies have become available for erenumab, there is a lack of real-world data pertaining to quality of life in the medium to long-term for chronic and treatment resistant migraine patients.